Zevra Therapeutics, Inc. Operating Lease, Weighted Average Discount Rate, Percent
Zevra Therapeutics, Inc. (ZVRA) had Operating Lease, Weighted Average Discount Rate, Percent of 14.30% as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-05
- 2026-06-30: Operating Lease, Weighted Average Discount Rate, Percent 14.30%.
- 2026-03-31: Operating Lease, Weighted Average Discount Rate, Percent 13.10%.
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 13.00%.
- 2025-09-30: Operating Lease, Weighted Average Discount Rate, Percent 12.90%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent |
|---|---|
| 2026-06-30 | 14.30% 10-Q · filed 2026-08-05 |
| 2026-03-31 | 13.10% 10-Q · filed 2026-05-06 |
| 2025-12-31 | 13.00% 10-Q · filed 2026-08-05 |
| 2025-09-30 | 12.90% 10-Q · filed 2025-11-05 |
| 2025-06-30 | 12.60% 10-Q · filed 2025-08-12 |
| 2025-03-31 | 12.30% 10-Q · filed 2025-05-13 |
| 2024-12-31 | 9.90% 10-K · filed 2026-03-09 |
| 2024-09-30 | 9.60% 10-Q · filed 2024-11-13 |
| 2024-06-30 | 8.50% 10-Q · filed 2024-08-14 |
| 2024-03-31 | 9.30% 10-Q · filed 2024-05-09 |
| 2023-12-31 | 7.60% 10-K · filed 2025-03-12 |
| 2023-09-30 | 7.50% 10-Q · filed 2023-11-07 |
| 2023-06-30 | 7.50% 10-Q · filed 2023-08-14 |
| 2023-03-31 | 7.40% 10-Q · filed 2023-05-15 |
| 2022-12-31 | 7.30% 10-K · filed 2024-04-01 |
| 2022-09-30 | 7.20% 10-Q · filed 2022-11-10 |
| 2022-06-30 | 7.20% 10-Q · filed 2022-08-12 |
| 2022-03-31 | 7.50% 10-Q · filed 2022-05-12 |
| 2021-12-31 | 7.50% 10-K · filed 2023-03-07 |
| 2021-09-30 | 7.50% 10-Q · filed 2021-11-10 |
| 2021-06-30 | 7.50% 10-Q · filed 2021-08-13 |
| 2021-03-31 | 7.50% 10-Q · filed 2021-05-14 |
| 2020-12-31 | 7.50% 10-K · filed 2022-03-31 |
| 2020-09-30 | 7.50% 10-Q · filed 2020-10-30 |
| 2020-06-30 | 7.50% 10-Q · filed 2020-08-12 |
| 2020-03-31 | 7.50% 10-Q · filed 2020-05-13 |
| 2019-12-31 | 7.50% 10-K · filed 2021-03-12 |
| 2019-09-30 | 7.50% 10-Q · filed 2019-11-14 |
| 2019-06-30 | 7.50% 10-Q · filed 2019-08-13 |
| 2019-03-31 | 7.50% 10-Q · filed 2019-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |